Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland.
Cannabidiol
Children
Chronic conditions
Medical cannabis
Seizures
Tetrahydrocannabinol
Treatment
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
13
05
2021
accepted:
07
07
2021
revised:
01
07
2021
pubmed:
27
7
2021
medline:
19
1
2022
entrez:
26
7
2021
Statut:
ppublish
Résumé
Evidence on the use and efficacy of medical cannabis for children is limited. We examined clinical and epidemiological characteristics of medical cannabis treatment and caregiver-reported effects in children and adolescents in Switzerland. We collected clinical data from children and adolescents (< 18 years) who received Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of the two between 2008 and 2019 in Switzerland. Out of 205 contacted families, 90 agreed to participate. The median age at the first prescription was 11.5 years (interquartile range (IQR) 6-16), and 32 patients were female (36%). Fifty-one (57%) patients received CBD only and 39 (43%) THC. Patients were more likely to receive THC therapy if one of the following symptoms or signs were present: spasticity, pain, lack of weight gain, vomiting, or nausea, whereas seizures were the dominant indication for CBD therapy. Improvements were reported in 59 (66%) study participants. The largest treatment effects were reported for pain, spasticity, and frequency of seizures in participants treated with THC, and for those treated with pure CBD, the frequency of seizures. However, 43% of caregivers reported treatment interruptions, mainly because of lack of improvement (56%), side effects (46%), the need for a gastric tube (44%), and cost considerations (23%).Conclusions: The effects of medical cannabis in children and adolescents with chronic conditions are unknown except for rare seizure disorders, but the caregiver-reported data analysed here may justify trials of medical cannabis with standardized concentrations of THC or CBD to assess its efficacy in the young. What is Known: • The use of medical cannabis (THC and CBD) to treat a variety of diseases among children and adolescents is increasing. • In contrast to adults, there is no evidence to support the use of medical cannabis to treat chronic pain and spasticity in children, but substantial evidence to support the use of CBD in children with rare seizure disorders. What is New: • This study provides important insights into prescription practices, dosages, and treatment outcomes in children and adolescents using medical cannabis data from a real-life setting. • The effects of medical cannabis in children and adolescents with chronic conditions shown in our study support trials of medical cannabis for chronic conditions.
Identifiants
pubmed: 34309706
doi: 10.1007/s00431-021-04202-z
pii: 10.1007/s00431-021-04202-z
pmc: PMC8760226
doi:
Substances chimiques
Medical Marijuana
0
Dronabinol
7J8897W37S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
335-347Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 174281
Informations de copyright
© 2021. The Author(s).
Références
Borgelt LM, Franson KL, Nussbaum AM, Wang GS (2013) The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 33(2):195–209
doi: 10.1002/phar.1187
Wong SS, Wilens TE (2017) Medical cannabinoids in children and adolescents: a systematic review. Pediatrics 140(5)
Fairhurst C, Kumar R, Checketts D, Tayo B, Turner S (2020) Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial. Dev Med Child Neurol 62(9):1031–1039
doi: 10.1111/dmcn.14548
Phillips RS, Friend AJ, Gibson F, Houghton E, Gopaul S, Craig JV et al (2016) Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2(2):Cd007786
Chan HS, Correia JA, MacLeod SM (1987) Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 79(6):946–952
pubmed: 3035479
Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA (2011) Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6(4):237–249
doi: 10.2174/157488611798280924
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M et al (2018) Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. New Eng J Med 378(20):1888–1897
doi: 10.1056/NEJMoa1714631
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R et al (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New Eng J Med 376(21):2011–2020
doi: 10.1056/NEJMoa1611618
Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL et al (2018) Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology 90(14):e1204–e1211
doi: 10.1212/WNL.0000000000005254
Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C et al (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 391(10125):1085–1096
doi: 10.1016/S0140-6736(18)30136-3
Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F et al (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 36(6):1219–1226
doi: 10.1038/npp.2011.6
Barchel D, Stolar O, De-Haan T, Ziv-Baran T, Saban N, Fuchs DO et al (2019) Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities. Front Pharmacol 9(1521)
Bar-Lev Schleider L, Mechoulam R, Saban N, Meiri G, Novack V (2019) Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep 9(1):200
doi: 10.1038/s41598-018-37570-y
Bundesrat (2018) Cannabis für Schwerkranke: Bericht des Bundesrates in Erfüllung der Motion 14.4164, Kessler, 11.12.2014. Bundesrat
Bundesrat (2020) 812.121 Bundesgesetz vom 3. Oktober 1951 über die Betäubungsmittel und die psychotropen Stoffe (Betäubungsmittelgesetz, BetmG) Bern Bundesrat; Available from: https://www.admin.ch/opc/de/classified-compilation/19981989/index.html
Praxis Suchtmedizin Schweiz (2018) CBD St. Gallen Praxis Suchtmedizin Schweiz; Available from: https://praxis-suchtmedizin.ch/praxis-suchtmedizin/index.php/de/cannabis/cbd
Kilcher G, Zwahlen M, Ritter C, Fenner L, Egger M (2017) Medical use of cannabis in Switzerland: analysis of approved exceptional licences. Swiss Med Wkly 147:w14463
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381
doi: 10.1016/j.jbi.2008.08.010
Praxis Suchtmedizin Schweiz (2019) Übersicht der gebräuchlichsten Cannabinoide in der Schweiz St.Gallen: Praxis Suchtmedizin Schweiz; Available from: https://www.praxis-suchtmedizin.ch/praxis-suchtmedizin/images/stories/cannabinoide/20191023_praeparate-galenik-hersteller-dosierung-kosten.pdf
Fankhauser M. Kompendium Cannabisprodukte der Bahnhof Apotheke Langnau AG LangnauNA. Available from: https://panakeia.ch/fileadmin/user_upload/Downloads/Cannabis/1_Kompendium__Cannabispraeparate_.pdf
Porter BE, Jacobson C (2013) Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 29(3):574–577
doi: 10.1016/j.yebeh.2013.08.037
Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S et al (2016) CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure 35:41–44
doi: 10.1016/j.seizure.2016.01.004
Hausman-Kedem M, Kramer U (2017) Efficacy of medical cannabis for treatment of refractory epilepsy in children and adolescents with emphasis on the Israeli experience. Isr Med Assoc J: IMAJ 19(2):76–78
pubmed: 28457054
de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E (2020) Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav 102:106635
Kuhlen M, Hoell JI, Gagnon G, Balzer S, Oommen PT, Borkhardt A et al (2016) Effective treatment of spasticity using dronabinol in pediatric palliative care. Eur J Paediatr Neurol 20(6):898–903
doi: 10.1016/j.ejpn.2016.07.021
Libzon S, Bar-Lev Schleider L, Saban N, Levit L, Tamari Y, Linder I et al (2018) Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders. J Child Neurol 33:088307381877302
doi: 10.1177/0883073818773028
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet 362(9395):1517–1526
doi: 10.1016/S0140-6736(03)14738-1
da Rovare VP, Magalhães GPA, Jardini GDA, Beraldo ML, Gameiro MO, Agarwal A et al (2017) Cannabinoids for spasticity due to multiple sclerosis or paraplegia: a systematic review and meta-analysis of randomized clinical trials. Complement Ther Med 34:170–185
doi: 10.1016/j.ctim.2017.08.010
Wade DT, Makela P, Robson P, House H, Bateman C (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler J 10(4):434–441
doi: 10.1191/1352458504ms1082oa
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV et al (2015) Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. Jama 313(24):2456–2473
doi: 10.1001/jama.2015.6358
Samanta D (2019) Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Pediatric neurology 96:24–29
doi: 10.1016/j.pediatrneurol.2019.03.014
Sundheds- og Ældreministeriet (2017) Vejledning om lægers behandling af patienter med medicinsk cannabis omfattet af forsøgsordningen Copenhagen: Sundheds- og Ældreministeriet; Available from: https://www.retsinformation.dk/eli/retsinfo/2018/9000
Queensland Health (2018) Clinical Guidance: for the use of medicinal cannabis products in Queensland Queensland: Queensland Health; Available from: https://www.health.qld.gov.au/__data/assets/pdf_file/0023/634163/med-cannabis-clinical-guide.pdf
Therapeutic Goods Administration (2020) Medicinal cannabis - guidance documents Woden ACT: Australian Government Department of Health; Available from: https://www.tga.gov.au/node/732373
Riechmann J, Strzelczyk A, Reese JP, Boor R, Stephani U, Langner C et al (2015) Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia 56(9):1388–1397
doi: 10.1111/epi.13089